Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway

J Neurosci. 2011 Aug 31;31(35):12629-37. doi: 10.1523/JNEUROSCI.0684-11.2011.

Abstract

Mutations in the methyl-CpG-binding protein 2 (MeCP2) result in Rett syndrome (RTT), an X-linked disorder that disrupts neurodevelopment. Girls with RTT exhibit motor deficits similar to those in Parkinson's disease, suggesting defects in the nigrostriatal pathway. This study examined age-dependent changes in dopamine neurons of the substantia nigra (SN) from wild-type, presymptomatic, and symptomatic Mecp2(+/-) mice. Mecp2(+) neurons in the SN in Mecp2(+/-) mice were indistinguishable in morphology, resting conductance, and dopamine current density from neurons in wild-type mice. However, the capacitance, total dendritic length, and resting conductance of Mecp2(-) neurons were less than those of Mecp2(+) neurons as early as 4 weeks after birth, before overt symptoms. These differences were maintained throughout life. In symptomatic Mecp2(+/-) mice, the current induced by activation of D(2) dopamine autoreceptors was significantly less in Mecp2(-) neurons than in Mecp2(+) neurons, although D(2) receptor density was unaltered in Mecp2(+/-) mice. Electrochemical measurements revealed that significantly less dopamine was released after stimulation of striatum in adult Mecp2(+/-) mice compared to wild type. The decrease in size and function of Mecp2(-) neurons observed in adult Mecp2(+/-) mice was recapitulated in dopamine neurons from symptomatic Mecp2(-/y) males. These results show that mutation in Mecp2 results in cell-autonomous defects in the SN early in life and throughout adulthood. Ultimately, dysfunction in terminal dopamine release and D(2) autoreceptor-dependent currents in dopamine neurons from symptomatic females support the idea that decreased dopamine transmission due to heterogeneous Mecp2 expression contributes to the parkinsonian features of RTT in Mecp2(+/-) mice.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Analysis of Variance
  • Animals
  • Benzamides / pharmacokinetics
  • Biophysics
  • Corpus Striatum / physiology*
  • Dopamine / metabolism*
  • Dopamine Antagonists / pharmacokinetics
  • Electric Stimulation / methods
  • Electrochemical Techniques / methods
  • Excitatory Amino Acid Antagonists / pharmacology
  • Female
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • In Vitro Techniques
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / genetics
  • Methyl-CpG-Binding Protein 2 / deficiency*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neural Conduction / drug effects
  • Neural Conduction / genetics
  • Neural Pathways / physiology*
  • Neurons / drug effects
  • Neurons / physiology*
  • Patch-Clamp Techniques / methods
  • Protein Binding / drug effects
  • Radioligand Assay
  • Sex Factors
  • Substantia Nigra / cytology*
  • Tritium / pharmacokinetics

Substances

  • Benzamides
  • Dopamine Antagonists
  • Excitatory Amino Acid Antagonists
  • Mecp2 protein, mouse
  • Methyl-CpG-Binding Protein 2
  • Tritium
  • nemonapride
  • Dopamine